Yes. Men's Scalp Solution is a compounded prescription topical preparation requiring a valid prescription from a licensed healthcare provider. A telehealth consultation and hair loss evaluation are required before dispensing to confirm the diagnosis and pattern of hair loss, screen for contraindications, and establish an appropriate treatment protocol.

Men's Scalp Solution is generally well tolerated at prescribed doses. Azelaic acid may cause mild scalp tingling, warmth, or transient dryness during the first one to two weeks of use. Topical testosterone and progesterone may cause mild scalp irritation or sensitivity at the application site; rare systemic hormonal effects including mood changes or shifts in libido are possible with significant absorption and should be reported to your provider. Liothyronine (T3) may cause palpitations, elevated heart rate, or restlessness if significant systemic absorption occurs, particularly in thyroid-sensitive patients. Transient increased shedding in weeks four to eight as follicles re-enter the anagen phase is expected and temporary. Report any persistent scalp reactions, cardiovascular symptoms, or unexpected hormonal changes to your provider promptly.

. Men with a history of prostate cancer, breast cancer, or hypersensitivity to any active ingredient in the formulation should not use this product without oncological evaluation. Patients with active scalp infections, significant inflammatory scalp conditions, or significant hepatic or cardiovascular conditions require individualized provider assessment before initiating treatment.

Patients on systemic testosterone replacement therapy (TRT) should disclose the topical testosterone component to all providers to avoid inadvertent androgen excess. Those on systemic thyroid medications including levothyroxine, desiccated thyroid, or systemic liothyronine require thyroid function monitoring and potential dose adjustment. Antithyroid medications (methimazole, propylthiouracil) may be partially counteracted by the liothyronine component. Patients on systemic HRT or oral contraceptives should ensure all providers are aware of the topical progesterone component. Beta-blockers and cardiovascular medications warrant disclosure due to the thyroid active. Copper-chelating topicals or high-dose zinc supplementation may interact with azelaic acid's enzymatic activity. Always provide a complete medication list before beginning treatment.

Patients with thyroid conditions, prostate disease, or those on TRT require provider review before starting. Lab monitoring is recommended for the T3 and testosterone components.